This non-comparative pilot study, including patients with Prosthetic Joint Infections (PJI), recruited 29 patients, 26 of whom were evaluable
PHAXIAM Therapeutics presents clinical data of the PhagoDAIR pilot study, with results confirming the design of the GLORIA Phase II clinical study
